MAXCYTE, INC. — Director's Dealing 2024

Oct 3, 2024

National Storage Mechanism | Additional information

RNS Number : 8297G

MaxCyte, Inc.

03 October 2024

MaxCyte, Inc.

("MaxCyte" or the "Company")

Exercise of options and PDMR dealing

ROCKVILLE, MD, October 3, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that between 1 October 2024 and 2 October 2024, as per a filing lodged with the U.S. Securities and Exchange Commission, Stanley Erck, a Non-Executive Director of the Company , exercised options over 47,689 shares of common stock of $0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 47,689 new shares of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold by Stanley Erck at a price range between $3.625 and $3.880 per Common Stock ("Sale"). The sold shares represent approximately 7.94% of Stanley Erck's total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise and Sale, Stanley Erck holds 247,751 shares of Common Stock representing 0.2% of the issued stock capital of the Company. Following the Exercise, Stanley Erck holds a further 324,190 options over Common Stock and 21,367 restricted stock units.

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Stanley Erck on 12 March 2024 relating solely to the sale of shares acquired from exercise of options that expire on 11 November 2024.

MaxCyte Contacts:

US IR Adviser Gilmartin Group David Deuchler, CFA	+1 415-937-5400 [email protected]
Nominated Adviser and Joint Corporate Broker Panmure Liberum Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden	+44 (0)20 7886 2500
UK IR Adviser ICR Consilium Mary-Jane Elliott Chris Welsh	+44 (0)203 709 5700 [email protected]

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn .

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stanley Erck
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common Stock of $0.01 each
Identification code	US57777K1060
b)	Nature of the transaction	Exercise of Options over common stock
c)	Price(s) and volume(s)
		Exercise Price(s)	Volume(s)
		$0.040	26,082
d)	Aggregated information
- Aggregated volume	26,082
- Price	$0.040
e)	Date of the transaction	1 October 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stanley Erck
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common Stock of $0.01 each
Identification code	US57777K1060
b)	Nature of the transaction	Sale of common stock
c)	Price(s) and volume(s)
		Exercise Price(s)	Volume(s)
		$3.6900	200
		$3.6950	1301
		$3.7000	200
		$3.7050	1600
		$3.7100	100
		$3.7150	900
		$3.7200	466
		$3.7300	1001
		$3.7350	1666
		$3.7400	200
		$3.7450	800
		$3.7500	349
		$3.7550	975
		$3.7650	2700
		$3.7700	700
		$3.7750	1700
		$3.7800	104
		$3.7850	1000
		$3.7950	1200
		$3.8000	200
		$3.8050	200
		$3.8150	1600
		$3.8200	200
		$3.8250	700
		$3.8300	607
		$3.8350	300
		$3.8400	200
		$3.8450	1500
		$3.8500	300
		$3.8600	600
		$3.8650	713
		$3.8700	1000
		$3.8750	100
		$3.8800	500
d)	Aggregated information
- Aggregated volume	26,082
- Price	$3.7784
e)	Date of the transaction	1 October 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stanley Erck
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common Stock of $0.01 each
Identification code	US57777K1060
b)	Nature of the transaction	Exercise of Options over common stock
c)	Price(s) and volume(s)
		Exercise Price(s)	Volume(s)
		$0.040	21,607
d)	Aggregated information
- Aggregated volume	21,607
- Price	$0.040
e)	Date of the transaction	2 October 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Stanley Erck
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Common Stock of $0.01 each
Identification code	US57777K1060
b)	Nature of the transaction	Sale of common stock
c)	Price(s) and volume(s)
		Exercise Price(s)	Volume(s)
		$3.6250	400
		$3.6300	200
		$3.6350	109
		$3.6400	300
		$3.6450	50
		$3.6500	13
		$3.6550	50
		$3.6600	200
		$3.6650	200
		$3.6700	400
		$3.6750	305
		$3.6800	1078
		$3.6850	525
		$3.6900	1700
		$3.7000	1037
		$3.7100	240
		$3.7150	1040
		$3.7200	9400
		$3.7210	900
		$3.7250	251
		$3.7400	467
		$3.7500	142
		$3.7650	100
		$3.7700	2500
d)	Aggregated information
- Aggregated volume	21,607
- Price	$3.7131
e)	Date of the transaction	2 October 2024
f)	Place of the transaction	US Stock Exchange, Nasdaq

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEAPEDELELFEA